In this study, our aim is to assess the psychological status of patients in whom anti-VEGF treatment for DME has been delayed, particularly the rate of depression, anxiety, and stress (DAS) among patients with affected vision due to the delayed treatment. This evidence concerns the gene VEGFA and depressive symptom measurement.